SCA Pharma
SCA Pharma is an FDA 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ready-to-use medications for U.S. hospital and healthcare facility pharmacies. It operates two cGMP-compliant compounding facilities and distributes through Vizient GPO and Medigi platforms.
- Company typePrivate
- Founded2017
- HeadquartersLittle Rock, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What SCA Pharma does
SCA Pharma is an FDA 503B outsourcing facility that compounds sterile admixtures and pre-filled syringes for hospital and healthcare facility pharmacies across the United States. The company operates two cGMP-compliant sterile compounding facilities — an Arkansas Manufacturing Facility in Little Rock (8821 Knoedl Court) and a 90,000-square-foot Connecticut Manufacturing Facility in Windsor (755 Rainbow Road) — totaling approximately 120,000 square feet of infrastructure. Licensed in 49 states and Washington, D.C., SCA Pharma serves hospital pharmacy customers through direct enterprise field sales, a customer portal (partner.scapharma.com), channel partnerships with Vizient and Medigi, and processes approximately 5,800 monthly shipments across a catalog of roughly 200 National Drug Codes spanning 15 therapeutic categories (firmographics and company history describe an operational founding in 2017 following an initial investment from Enhanced Healthcare Partners, though firmographic records list 2009 for the legal entity; this conflict is noted and not resolved by the available data).
The company's product portfolio covers critical care, labor and delivery, anesthesia, and pain management applications, with named products including Hydromorphone HCl, Sugammadex, Ketamine HCl, and Potassium Phosphate. SCA Pharma was the first 503B outsourcing facility to embed Kit Check RFID tags on all products and operates advanced rapid microbiological testing infrastructure including the Celsis rapid detection platform, Charles River Endosafe-MCS endotoxin testing, and Rapid Micro Biosystems Growth Direct, supported by HPLC/UPLC chromatography for assay and impurity determination. Quality operations are managed through a validated MasterControl electronic Quality Management System aligned with ICH Q10 and ICH Q9(R1) principles and staffed by 90+ quality personnel and 20 licensed pharmacists.
SCA Pharma generates revenue through the sale of compounded pharmaceutical products to hospital and healthcare facility pharmacies via direct sales teams, an online customer portal, and third-party purchasing platforms. A multi-year agreement with Vizient — a healthcare performance improvement company whose member network includes over 60% of U.S. healthcare organizations — provides significant distribution reach. Extended Beyond Use Date (BUD) programs — covering 69 products with BUDs up to 180 days — and guaranteed next-business-day shipping on Buy & Ship Now orders support inventory efficiency for pharmacy customers. SCA Pharma was acquired in January 2021 by The Vistria Group and Excellere Partners and is led by CEO Scott Luce, supported by a leadership team including COO Matt White (PharmD), CQO Ken Bonnell (formerly of Aldevron/Danaher, Merck, and PCI Pharma), CHRO Steven Dufort, and VP of Sales & Customer Experience Jessica Wrentz.
SCA Pharma firmographics
Firmographics- Name
- SCA Pharma
- Legal name
- SCA Pharmaceuticals, LLC
- Website
- https://scapharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- SCA Pharma is an FDA 503B outsourcing facility producing sterile admixtures, pre-filled syringes, and ready-to-use medications for U.S. hospital and healthcare facility pharmacies. It operates two cGMP-compliant compounding facilities and distributes through Vizient GPO and Medigi platforms.
- Ownership category
- akta.pro rank
Where SCA Pharma is headquartered
LocationHeadquarters
- HQ city
- Little Rock
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
SCA Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Compounded Pharmaceutical Products: SCA Pharma generates revenue through the sale of FDA 503B compliant sterile compounded pharmaceuticals including sterile admixtures, pre-filled syringes, and ready-to-use medications to hospital and healthcare facility pharmacies. Products are sold through direct sales teams, customer portal, and distribution partnerships.
- Platform Distribution: Revenue from distributing core pharmaceutical products through third-party purchasing platforms such as Medigi, expanding market reach beyond direct customer relationships.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
SCA Pharma product offering
Product offeringCore offering
SCA Pharma is an FDA 503B outsourcing facility that compounds and supplies sterile admixtures (IV bags) and pre-filled syringes — including ready-to-use and drug-shortage medications — to hospital and healthcare facility pharmacies from cGMP-compliant facilities in Little Rock, Arkansas and Windsor, Connecticut. The portfolio comprises approximately 200 product NDCs across 15 therapeutic categories, with extended Beyond Use Dating, RFID-enabled medication intelligence, and rapid sterility and endotoxin testing.
Product overview
SCA Pharma is an FDA 503B outsourcing facility providing hospital and healthcare facility pharmacies with sterile compounded medications. The company operates two state-of-the-art facilities (Little Rock, Arkansas and Windsor, Connecticut) and offers a portfolio centered on sterile admixtures (IV bags) and pre-filled syringes. The product portfolio includes approximately 200 Product NDCs across 15 product categories, serving critical care, labor and delivery, anesthesia, and pain management therapeutic areas. Key products include Hydromorphone HCl (pain management), Sugammadex (neuromuscular blockade reversal), and Ketamine HCl (anesthesia), as well as ready-to-use and drug-shortage medications. The company differentiates through cGMP compliance, extended Beyond Use Dating (BUD) programs, RFID-enabled medication intelligence via Kit Check, and multi-platform distribution through Vizient, Medigi, and direct sales channels.
Differentiator
Problem solved
Functional benefit
Products and services
- Sterile Admixtures (IV Bags) Compounded sterile admixture IV bag products in 0.9% Sodium Chloride and other diluents spanning pain management, electrolyte replacement, and critical care — ready-to-use for hospital administration.
- Pre-filled Syringes Pre-filled syringes in various concentrations and volumes (e.g., 50 mg/5 mL) for anesthesia, neuromuscular blockade reversal, pain management, and other critical care applications — ready-to-use and RFID-tagged for medication intelligence.
- Hydromorphone HCl Products Hydromorphone HCl sterile admixtures in 0.9% Sodium Chloride in multiple concentrations and bag sizes for hospital pain management.
- Sugammadex Products Sugammadex sterile pre-filled syringes for reversal of neuromuscular blockade, with extended Beyond Use Dating (up to 120 days) for inventory flexibility.
- Ketamine HCl Ketamine HCl 50 mg/mL pre-filled syringe (1 mL in 3 mL syringe) for anesthesia and pain management, with Beyond Use Dating up to 180 days.
- Potassium Phosphate Potassium Phosphate 15 mMol in 0.9% Sodium Chloride 250 mL IV bag for electrolyte replacement in hospitalized patients.
Quantifiable outcome
- Produced over 4 million patient doses in 2017 from the Little Rock facility alone
- +2 more outcomes
Companies that use SCA Pharma
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
SCA Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature8 records
SCA Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- MedigicoreSCA Pharma expanded distribution of core pharmaceutical products to Medigi as an alternate purchasing location. This partnership ensures healthcare professionals can access SCA Pharma's trusted offerings through a broader network of purchasing platforms, improving accessibility and supporting continuity of care.
- VizientcoreSCA Pharma was awarded a multi-year agreement by Vizient for its full range of 503B ready-to-use products. Vizient is one of the nation's leading healthcare performance improvement companies trusted by over 60% of U.S. health care organizations. An independent third-party cGMP assessment was completed as a requirement for the contract, confirming both SCA facilities produce high-quality, safe, and efficacious products.
- Kit CheckcoreSCA Pharma partnered with Kit Check, a leader in automated and intelligent medication management solutions. SCA Pharma was the first 503B outsourcing facility to use Kit Check's embedded RFID tag on all products, providing medication intelligence and enhancing safety verification for customers.
- DoseID ConsortiumminorSCA Pharma joined the DoseID consortium, the first member-driven industry consortium dedicated to the use of radio-frequency identification (RFID) technology in healthcare, with the goal of ensuring performance, quality, and accuracy of RFID-tagged drug products.
- Bausch Advanced TechnologiesminorDuring COVID-19 pandemic, SCA Pharma partnered with Bausch Advanced Technologies to compound and distribute over 2,500 containers of alcohol-based hand sanitizer at no cost to first responders and front-line healthcare workers in Connecticut.
- Health Connect PartnersminorSCA Pharma participates in Health Connect Partners Hospital Pharmacy conferences (spring and fall), exhibiting and sharing information about quality initiatives, product portfolio, and facility virtual tours.
Scale indicators8 records
Recent moves10 records
Expansion highlights6 records
SCA Pharma competitors and assessment
Company assessmentDirect peers
- QuVa Pharma: QuVa Pharma is a leading FDA 503B outsourcing facility producing sterile admixtures and pre-filled syringes for hospital and health-system pharmacies. QuVa competes head-to-head with SCA across the same 503B product categories, customer base (US hospitals), and regulatory framework, making it the most direct comparable.
- Leiters Health: Leiters Health is an FDA 503B outsourcing facility providing ready-to-use sterile admixtures, pre-filled syringes, and ophthalmic preparations to hospital and health-system pharmacies. Directly comparable to SCA on regulatory regime, product format (sterile admixtures and prefilled syringes), and target customer (US hospital pharmacies).
- Central Admixture Pharmacy Services (CAPS): CAPS is one of the largest 503B and centralized admixture compounding pharmacy networks in the U.S., serving hospital pharmacies with compounded sterile preparations. Comparable to SCA in regulatory positioning (503B), service offering (sterile admixtures), and customer base (US hospitals).
- Pharmedium Services: Pharmedium (a Cencora/AmerisourceBergen business) operates a national network of 503B compounding pharmacies producing sterile admixtures and prefilled syringes for hospitals. A direct competitor to SCA in 503B sterile outsourcing with similar product categories, national distribution, and GPO-driven hospital customer base.
Emerging players
- Olympia Pharmaceuticals: Olympia Pharmaceuticals operates as a 503B outsourcing facility offering compounded sterile preparations and repackaged pharmaceutical products to hospital and clinical customers. Smaller and more regionally focused than SCA but competing in the same 503B regulatory and product category.
- Wells Pharma of Houston: Wells Pharma of Houston is an FDA 503B registered outsourcing facility providing sterile admixtures and pre-filled syringes to hospital pharmacies. A smaller 503B peer with overlapping product format and customer base as SCA, though with a more limited national footprint.
Broad incumbents
- B. Braun Medical: B. Braun is a major medical device and pharmaceutical solutions company with a large IV solutions, infusion therapy, and sterile compounding/admixture portfolio serving US hospitals. Comparable as a broader incumbent that competes for hospital pharmacy wallet share, particularly on IV solutions and compounded sterile preparations.
- Baxter International: Baxter is a global healthcare company with significant hospital pharmacy and sterile injectable/IV solutions franchises, including a broader portfolio than SCA. Relevant incumbent competitor in hospital pharmacy sourcing decisions, especially for IV admixtures and ready-to-administer products.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
SCA Pharma social profiles
Digital presenceSCA Pharma compliance and trust
Trust signalCompliance6 records
SCA Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
SCA Pharma leadership team
Management profileNumber of profiles
Profiles7 records
SCA Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SCA Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SCA Pharma
What does SCA Pharma do?
SCA Pharma is an FDA 503B outsourcing facility that compounds and supplies sterile admixtures (IV bags) and pre-filled syringes — including ready-to-use and drug-shortage medications — to hospital and healthcare facility pharmacies from cGMP-compliant facilities in Little Rock, Arkansas and Windsor, Connecticut. The portfolio comprises approximately 200 product NDCs across 15 therapeutic categories, with extended Beyond Use Dating, RFID-enabled medication intelligence, and rapid sterility and endotoxin testing.
Is SCA Pharma a public or private company?
SCA Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was SCA Pharma founded?
SCA Pharma was founded in 2017. It employs 501 to 1,000 people.
Where is SCA Pharma based?
SCA Pharma is headquartered in Little Rock, United States, in the North America region.
How does SCA Pharma make money?
Two revenue lines are on record. Compounded Pharmaceutical Products are the primary driver. The others are platform Distribution.
Who are SCA Pharma's main competitors?
Direct peers on record are QuVa Pharma, Leiters Health, Central Admixture Pharmacy Services (CAPS) and Pharmedium Services. Emerging players are Olympia Pharmaceuticals and Wells Pharma of Houston. Broad incumbents are B. Braun Medical and Baxter International.
Does SCA Pharma have an API?
No public API is recorded for SCA Pharma.